Saturday, October 24, 2020
Pharma New Releases

Latest articles in New Releases

FDA Approves Drug Combination for Treating Mesothelioma

First approval in 16 years for mesothelioma, a type of cancer caused by inhaling asbestos fibers

Phexxi; Have You Heard About This New Hormone-Free Contraceptive?

She is sick of using birth control, but now is not the right time to get pregnant....

Parnell Pharmaceuticals Announces Nomovid™ Antiviral Nasal Spray

The first antiviral nasal spray in the United States. Nomovid™ Nasal Spray will be easy-to-use, low-cost and can be quickly made available over-the-counter for consumers.

Is Silmitasertib the Covid-19 Treatment Breakthrough We’ve Been Waiting for?

Within 24 hours of the first dose of Silmitasertib the patient showed significant clinical improvement and the oxygen requirement was weaned to room air. The patient was discharged from the hospital five days after starting Silmitasertib.

Arjuna Unveils New Botanical Analgesic Blend

The three botanicals are synergistically blended with a unique proprietary technology to provide fast relief of acute musculoskeletal pain.

SPRAVATO® (esketamine) CIII Nasal Spray to Treat Depressive Symptoms in Adults Approved

SPRAVATO® (esketamine) CIII nasal spray, taken with an oral antidepressant, to treat depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior.

Evrysdi™ Approved for Spinal Muscular Atrophy Home Treatment

The FDA has approved Evrysdi™ (risdiplam), the first at-home, orally administered treatment for spinal muscular atrophy in children and adults

FDA Approves New Opioid, Olinvyk, for Intravenous Use in Hospitals

the U.S. Food and Drug Administration approved Olinvyk (oliceridine), an opioid agonist for the management of moderate to severe acute pain in adults

FDA approves Ready-to-Use Ephedrine Injection, Emerphed™

Nexus Pharmaceuticals, Inc. Announces Approval of Emerphed™ (ephedrine sulfate) Injection, the First and Only FDA-approved, Ready-to-Use Ephedrine Injection (50 mg/10 mL vial)

Opdivo® Approved for the Treatment of Advanced Esophageal Squamous Cell Carcinoma

FDA Approved Opdivo demonstrated superior overall survival benefit compared to docetaxel or paclitaxel in ESCC Patients

ZEPOSIA® (ozanimod), a New Oral Treatment for Relapsing Forms of Multiple Sclerosis

ZEPOSIA, a treatment for multiple sclerosis is the first and only approved sphingosine-1-phosphate (S1P) receptor modulator with no genetic test or first dose observation at initiation

Reblozyl (luspatercept) Approved for Treatment of Transfusion-Dependent Anemia

European Commission Approves Reblozyl (luspatercept) for the Treatment of Transfusion-Dependent Anemia in Adult Patients with Myelodysplastic Syndromes or Beta Thalassemia

Editors Choice

ZEPOSIA® (ozanimod), a New Oral Treatment for Relapsing Forms of Multiple...

ZEPOSIA, a treatment for multiple sclerosis is the first and only approved sphingosine-1-phosphate (S1P) receptor modulator with no genetic test or first dose observation at initiation

Parnell Pharmaceuticals Announces Nomovid™ Antiviral Nasal Spray

The first antiviral nasal spray in the United States. Nomovid™ Nasal Spray will be easy-to-use, low-cost and can be quickly made available over-the-counter for consumers.

Reblozyl (luspatercept) Approved for Treatment of Transfusion-Dependent Anemia

European Commission Approves Reblozyl (luspatercept) for the Treatment of Transfusion-Dependent Anemia in Adult Patients with Myelodysplastic Syndromes or Beta Thalassemia